Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urology and Nephrology 2021 August;73(4) > Minerva Urology and Nephrology 2021 August;73(4):540-3

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

SHORT COMMUNICATION   

Minerva Urology and Nephrology 2021 August;73(4):540-3

DOI: 10.23736/S2724-6051.20.04151-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Robot-assisted partial nephrectomy: 7-year outcomes

Umberto CARBONARA 1, 2, Giuseppe SIMONE 3, Umberto CAPITANIO 4, 5, Andrea MINERVINI 6, Cristian FIORI 7, Alessandro LARCHER 4, 5, Enrico CHECCUCCI 7, Daniele AMPARORE 7, Fabio CROCEROSSA 1, Alessandro VECCIA 1, Samuel WEPRIN 1, Pasquale DITONNO 2, 8, Aldo BRASSETTI 3, Alfredo BOVE 3, Andrea MARI 6, Antonio Andrea GROSSO 6, Marco CARINI 6, Francesco MONTORSI 4, 5, Lance J. HAMPTON 1, Michele GALLUCCI 9, Francesco PORPIGLIA 7, Riccardo AUTORINO 1

1 Division of Urology, VCU Health, Richmond, VA, USA; 2 Department of Urology, University of Bari, Bari, Italy; 3 Department of Urology, Regina Elena Institute, Rome, Italy; 4 Unit of Urology, IRCCS San Raffaele Hospital, Milan, Italy; 5 Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Hospital, Milan, Italy; 6 Department of Urology, Careggi Hospital, University of Florence, Florence, Italy; 7 Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; 8 Unit of Urology, Giovanni Paolo II National Cancer Institute IRCCS, Bari, Italy; 9 Department of Urology, Sapienza University, Rome, Italy



BACKGROUND: The role of robot-assisted partial nephrectomy (RAPN) in the management of renal masses has exponentially grown over the past 10 years. Nevertheless, data on long term outcomes of the procedure remains limited. Herein we report oncological and functional outcomes of patients who underwent RAPN for a malignant mass with a median follow-up of 7 years, the longest follow-up to date.
METHODS: A retrospective analysis of an international multicenter database was performed. All consecutive patients undergoing surgery between 2009 and 2013 with a minimum of 3-year follow-up and complete data on renal function were included. Demographics, surgical and perioperative outcomes were analyzed. Overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) were evaluated using Kaplan-Meier analysis.
RESULTS: Overall, our study cohort was composed of eighty-five patients with a median follow-up of 88 months. Median clinical tumor size was 3 cm, with mostly (74.1%) clinical stage T1a, and median RENAL score 6. Final histopathologic analysis revealed clear cell RCC in 76.5% of cases. PSM was present in seven patients (8.2%). Eleven overall deaths (12.9%) occurred in the cohort during the follow-up period. Two of these (2.33%) were attributed to metastatic RCC. The OS, CSS, and DFS rates were 91.7%, 97.7%, and 91.7% at 84 months, respectively. Regarding the renal functional outcomes, seventeen patients (20.1%) presented a CKD upstaging in our cohort.
CONCLUSIONS: Our findings show excellent 7-year oncologic and functional outcomes of the procedure, which duplicate those achieved in historical series of open and laparoscopic surgery.


KEY WORDS: Robotic surgical procedures; Nephrectomy; Halthcare outcome assessment

inizio pagina